ArticleFrontiers in oncology2025
Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with ovarian cancer experience disease recurrence or progression, and ultimately progress to platinum resistance. Standard treatments for platinum-resistant ovarian cancer (PROC) include non-platinum chemotherapy, targeted agents, and immunotherapy. Despite recent advances in individualized management of PROC, median progression-free survival remains limited. Effective treatments are still lacking for PROC treatment. Given the current landscape of immunotherapy in ovarian cancer, research is ongoing to investigate immune modulators to counteract immune escape and enhance the efficacy of immune checkpoint inhibitors. Here, we reported a successful administration of a triple regimen comprising pembrolizumab, lenvatinib and metronomic cyclophosphamide, as the third-line treatment in a patient with PROC. This combination resulted in a durable response, with a PFS of 52 months as of the last follow up. This is the first report on this triple regimen in PROC and its promising outcome suggested that this regimen deserves further investigation as a potential therapeutic option for PROC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.